Source recordFED

Laurent Pharmaceuticals Inc.

Federal grants & contributions· Industrial Research Assistance Program – Contributions to Firms· National Research Council Canada· FY2021· $10,000,000· BN 835517442· QC

Description

Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.

Amendment chain · 4 entries

Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $4,166,796 at start, $10,000,000 after amendment #4 (+$5,833,204).

$10,000,000$0Original · 2020-12-24 · total $4,166,796Amendment 2 · 2021-06-15 · total $6,425,932Amendment 3 · 2022-01-04 · total $10,000,000Amendment 4 · 2022-11-28 · total $10,000,000
  • #12020-12-24$4,166,796
  • #22021-06-15$6,425,932+$2,259,136
  • #32022-01-04$10,000,000+$3,574,068
  • #42022-11-28$10,000,000
RowDateTotal value as of rowChange vs previousDescription on this row
#0 original2020-12-24$4,166,796—Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
#2 amendment2021-06-15$6,425,932+$2,259,136Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
#3 amendment2022-01-04$10,000,000+$3,574,068Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
#4 amendment2022-11-28$10,000,000+$0Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.

Related records · 10

Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).

Other current agreements for the same recipient (business number 835517442)

RefDepartment · programCurrent valueFY
172-2022-2023-Q4-1002706National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$7,000,000FY2023
172-2020-2021-Q4-967293National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program$21,676FY2021
172-2020-2021-Q3-960877National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program$48,704FY2021
172-2020-2021-Q1-949490National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program$40,656FY2021
172-2019-2020-Q3-939069National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$665,000FY2020

Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)

RefRecipientFiscal yearCurrent valueFY
172-2025-2026-Q2-1034675Mediphage Bioceuticals, Inc.FY2027$63,380FY2027
172-2025-2026-Q3-1037522OBKIO INC.FY2026$50,000FY2026
172-2025-2026-Q3-1037889SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INCFY2026$25,000FY2026
172-2025-2026-Q2-1034040Griffith Foods LimitedFY2026$54,880FY2026
172-2025-2026-Q3-1037273Apollo Machine & Welding Ltd.FY2026$230,000FY2026

Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-958708 · retrieved 2026-11-16.